AbbVie's Skyrizi posts ulcerative colitis win in maintenance study, teeing up FDA nod

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jun 16, 2023 at 10:32: AM
via After acing a study for the induction treatment of ulcerative colitis, AbbVie’s Skyrizi has snatched another win in a maintenance trial. An approval now looks within reach for 2024.

article source
 

<



Similar threads

cafead
FDA approves Abbvie&#039;s Skyrizi for ulcerative colitis
Replies
0
Views
44
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
AbbVie trumpets Skyrizi&#039;s resounding win against J&amp;J&#039;s Stelara in...
Replies
0
Views
288
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
AbbVie&#039;s Skyrizi delivers head-to-head win versus Amgen&#039;s Otezla in psoriasis
Replies
0
Views
183
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
AbbVie&#039;s Skyrizi aces ulcerative colitis study en route to new IBD showdown with...
Replies
0
Views
208
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
BMS&#039; Zeposia and AbbVie&#039;s Skyrizi Shake Up First-Line Prescribing Patterns in the...
Replies
0
Views
211
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote